COVID-19 vaccines were developed with an unprecedented pace since the beginning of the pandemic. Several of them have reached market authorization and mass production, leading to their global application on a large scale. This enormous progress was achieved with fundamentally different vaccine technologies used in parallel. mRNA, adenoviral vector as well as inactivated whole-virus vaccines are now in widespread use, and a subunit vaccine is in a final stage of authorization. They all rely on the native viral spike protein (S) of SARS-CoV-2 for inducing potently neutralizing antibodies, but the presentation of this key antigen to the immune system differs substantially between the different categories of vaccines. In this article, we review the relevance of structural modifications of S in different vaccines and the different modes of antigen expression after vaccination with genetic adenovirus-vector and mRNA vaccines. Distinguishing characteristics and unknown features are highlighted in the context of protective antibody responses and reactogenicity of vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368295 | PMC |
| http://dx.doi.org/10.1038/s41541-021-00369-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries.
Vaccine
January 2025
Instituto Butantan, Sao Paulo, Brazil.
Developing Countries Vaccine Manufacturers Network (DCVMN) is an alliance of vaccine developers, manufacturers, and marketing authorization holders (MAHs) from low- and middle-income countries (LMICs) that plays a vital role in ensuring equitable, inclusive, accountable, and timely access to affordable, high-quality vaccines in these countries. Besides research and development, this network promotes manufacturing and global supply chains for effective strengthening of regulatory and pharmacovigilance activities. Traditionally, vaccine safety surveillance systems in LMICs rely on spontaneous reporting.
View Article and Find Full Text PDFMicro and macropolitical determinants for non-vaccination against COVID-19 in pregnant women in Belo Horizonte.
Rev Bras Enferm
January 2025
Universidade Federal de Minas Gerais. Belo Horizonte, Minas Gerais, Brazil.
Objective: To analyze the determinants for non-vaccination against COVID-19 in pregnant women in Belo Horizonte, Minas Gerais, Brazil.
Methods: An epidemiological study with a cross-sectional design was conducted using data from the project titled "Childbirth and Breastfeeding in Children of Mothers Infected by SARS-CoV-2," developed during the pandemic in the city of Belo Horizonte, Minas Gerais, Brazil.
Results: The study sample consisted of 360 pregnant women, of whom 77.
Dynamics and triggers of misinformation on vaccines.
PLoS One
January 2025
Centro Ricerche Enrico Fermi, Rome, Italy.
The Covid-19 pandemic has sparked renewed attention to the risks of online misinformation, emphasizing its impact on individuals' quality of life through the spread of health-related myths and misconceptions. In this study, we analyze 6 years (2016-2021) of Italian vaccine debate across diverse social media platforms (Facebook, Instagram, Twitter, YouTube), encompassing all major news sources-both questionable and reliable. We first use the symbolic transfer entropy analysis of news production time-series to dynamically determine which category of sources, questionable or reliable, causally drives the agenda on vaccines.
View Article and Find Full Text PDFBuilding a Fast Response Capability for Emerging Infectious Diseases Within the Biomedical Advanced Research and Development Authority.
Health Secur
January 2025
Robert A. Johnson, PhD, is Director, Medical Countermeasures Programs, and Gary L. Disbrow, PhD, is Director, Center for Biomedical Advanced Research and Development Authority (BARDA), Washington, DC. Terence M. Barnhart, PhD, is Senior Strategy Implementation Leader, Tunnell Government Services, Inc. (Contractor Supporting BARDA), Washington, DC.
From influenza to COVID-19, emerging infectious diseases have taken a heavy toll on lives and resources. Emerging infectious diseases represent one of the largest threats to national security. The primary mission of the Center for Biomedical Advanced Research and Development Authority (BARDA), within the US Administration for Strategic Preparedness and Response, is to support the advanced development of medical countermeasures (MCMs) for public health security threats, including select infectious diseases.
View Article and Find Full Text PDF[Pharmacovigilance of COVID-19 Vaccines in Brazil: Actions Taken, Lessons Learned, and Next StepsFarmacovigilancia de las vacunas contra la COVID-19 en Brasil: medidas adoptadas, enseñanzas extraídas y próximos pasos].
Rev Panam Salud Publica
January 2025
Ministério da Saúde Brasília-DF Brasil Ministério da Saúde, Brasília-DF, Brasil.
Objective: To document the actions taken by Brazil's National Immunization Program for the pharmacovigilance of COVID-19 vaccines.
Methods: Documentary research on the period 2020 to 2023. Documentary sources from the national Ministry of Health during COVID-19 vaccination were used to analyze and interpret the actions taken.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!